Tag : CHECKMATE 816 STUDY

CONFERENCE UPDATE

Nivolumab + chemotherapy improves long-term survival outcomes in resectable NSCLC: Final OS analysis from the CheckMate 816 trial
In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.